Search for other works by this author on: ...

Title: ROSELLA: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72 ...

will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology ...

Title: ROSELLA: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72) The ...

Chongqing Materials Research Institute Co., Ltd, No. 8, Jiade Road, Caijiagang Town, Beibei, Chongqing 400707, China National Engineering Research Center for ...

1The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom.

MDX Research Center for Element Strategy, Institute of Integrated Research, Institute of Science Tokyo, 4259 Nagatsuta, Midori, Yokohama 226-8501, Japan MDX Research Center for Element Strategy, ...

Previously, in a multicenter Phase 1/2 study in participants with advanced solid tumors, a total of 87 participants with platinum-resistant ovarian cancer were enrolled and were treated with 6-12 ...

Previously, in a multicenter Phase 1/2 study in participants with advanced solid tumors, a total of 87 participants with platinum-resistant ovarian cancer were enrolled and were treated with 6-12 ...